Thrombolysis in the developing world: Is there a role for streptokinase?

International Journal of Stroke

Volumn 8, Issue 7, 2013, Pages 560-565

  Butcher, Ken ^a   Shuaib, Ashfaq ^a   Saver, Jeffrey ^b   Donnan, Geoffrey ^c   Davis, Stephen M ^c   Norrving, Bo ^d   Wong, K S Lawrence ^e   Abd Allah, Foad ^f   Bhatia, Rohit ^g   Khan, Adnan ^h  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d LUND UNIVERSITY   (Sweden)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f CAIRO UNIVERSITY   (Egypt)

^g ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^h KHYBER TEACHING HOSPITAL   (Pakistan)

Author keywords

Acute stroke therapy; Clinical trial; Cost factors; Developing countries; Ischemic stroke; Thrombolysis

Indexed keywords

HEPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; DEVELOPING COUNTRY; DISEASE SEVERITY; FIBRINOLYTIC THERAPY; HEALTH CARE COST; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW; TIME TO TREATMENT;

ACUTE STROKE THERAPY; CLINICAL TRIAL; COST FACTORS; DEVELOPING COUNTRIES; ISCHEMIC STROKE; THROMBOLYSIS;

DEVELOPING COUNTRIES; FIBRINOLYTIC AGENTS; HUMANS; STREPTOKINASE; STROKE; THROMBOLYTIC THERAPY;

EID: 84884332329     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2012.00923.x     Document Type: Review

References (47)

1. Mackay J and Mesah G. The Atlas of Heart Disease and Stroke 2004. The World Health Organization, Geneva.
2. Kim AS, Johnston SC. Global variation in the relative burden of stroke and ischemic heart disease. Circulation 2011; 124:314-323.
3. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009; 8:355-369.
4. Das SK, Banerjee TK. Stroke: Indian scenario. Circulation 2008; 118:2719-2724.
5. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581-1587.
6. Hacke W, Kaste M, Bluhmki E etal. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359:1317-1329.
7. Adams HP Jr, del Zoppo G, Alberts MJ etal. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38:1655-1711.
8. Feigin VL. Stroke in developing countries: can the epidemic be stopped and outcomes improved? Lancet Neurol 2007; 6:94-97.
9. Brainin M, Teuschl Y, Kalra L. Acute treatment and long-term management of stroke in developing countries. Lancet Neurol 2007; 6:553-561.
10. Boland A, Dundar Y, Bagust A etal. Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation. Health Technol Assess 2003; 7:1-136.
11. Dundar Y, Hill R, Dickson R, Walley T. Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review. QJM 2003; 96:103-113.
12. Donnan GA, Davis SM, Chambers B etal. Streptokinase for acute ischaemic stroke with relationship to time of administration. JAMA 1996; 276:961-966.
13. The Multicentre Acute Stroke Trial - Europe study G. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996; 335:145-150.
14. Multicentre Acute Stroke Trial - Italy G. Randomised controlled trial of streptokinase, aspirin and combination of both in treatment of acute ischaemic stroke. Lancet 1995; 346:1509-1514.
15. Morris AD, Ritchie C, Grosset DG, Adams FG, Lees KR. A pilot study of streptokinase for acute cerebral infarction. QJM 1995; 88:727-731.
16. Cornu C, Boutitie F, Candelise L etal. Streptokinase in acute ischemic stroke: an individual patient data meta-analysis: the Thrombolysis in Acute Stroke Pooling Project. Stroke 2000; 31:1555-1560.
17. Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2009, issue 4, art. no.: CD000213.
18. Haley EC Jr, Levy DE, Brott TG etal. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992; 23:641-645.
19. Brott TG, Haley EC Jr, Levy DE etal. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23:632-640.
20. The Multicenter Acute Stroke Trial - Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996; 335:145-150.
21. Sikri N, Bardia A. A history of streptokinase use in acute myocardial infarction. Tex Heart Inst J 2007; 34:318-327.
22. Ciccone A, Motto C, Aritzu E, Piana A, Candelise L. Negative interaction of aspirin and streptokinase in acute ischemic stroke: further analysis of the Multicenter Acute Stroke Trial - Italy. Cerebrovasc Dis 2000; 10:61-64.
23. Donnan GA, Davis SM, Chambers BR etal. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996; 276:961-966.
24. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997; 28:2109-2118.
25. Jaillard A, Cornu C, Durieux A etal. Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. MAST-E group. Stroke 1999; 30:1326-1332.
26. Jaillard A, Hommel M, Baird AE etal. Significance of early CT signs in acute stroke. A CT scan-diffusion MRI study. Cerebrovasc Dis 2002; 13:47-56.
27. Hill MD, Rowley HA, Adler F etal. Selection of acute ischemic stroke patients for intra-arterial thrombolysis with pro-urokinase by using ASPECTS. Stroke 2003; 34:1925-1931.
28. Hacke W, Kaste M, Fieschi C. Randomised double-blind placebo controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352:1245-1251.
29. Hacke W, Albers G, Al-Rawi Y etal. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36:66-73.
30. Butcher K, Christensen S, Parsons M etal. Postthrombolysis blood pressure elevation is associated with hemorrhagic transformation. Stroke 2010; 41:72-77.
31. Gilligan AK, Markus R, Read S etal. Baseline blood pressure but not early computed tomography changes predicts major hemorrhage after streptokinase in acute ischemic stroke. Stroke 2002; 33:2236-2242.
32. Molina CA, Saver JL. Extending reperfusion therapy for acute ischemic stroke: emerging pharmacological, mechanical, and imaging strategies. Stroke 2005; 36:2311-2320.
33. Fagan SC, Morgenstern LB, Petitta A etal. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology 1998; 50:883-890.
34. Diwedi SK, Hiremath JS, Kerkar PG etal. Indigenous recombinant streptokinase vs natural streptokinase in acute myocardial infarction patients: phase III multicentric randomized double blind trial. Indian J Med Sci 2005; 59:200-207.
35. Alpert JS. Importance of the pharmacological profile of thrombolytic agents in clinical practice. Am J Cardiol 1991; 68:3E-7E.
36. Sakharov DV, Barrertt-Bergshoeff M, Hekkenberg RT, Rijken DC. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro. Thromb Haemost 1999; 81:605-612.
37. Granger CB, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial infarction. A review. Drugs 1992; 44:293-325.
38. White HD. Comparison of tissue plasminogen activator and streptokinase in the management of acute myocardial infarction. Chest 1989; 95(5 Suppl.):265S-269.
39. Berridge DC, Earnshaw JJ, Westby JC, Makin GS, Hopkinson BR. Fibrinolytic profiles in local low-dose thrombolysis with streptokinase and recombinant tissue plasminogen activator. Thromb Haemost 1989; 61:275-278.
40. Ostermann H, Schmitz-Huebner U, Windeler J, Bar F, Meyer J, van de Loo J. Rate of fibrinogen breakdown related to coronary patency and bleeding complications in patients with thrombolysis in acute myocardial infarction - results from the PRIMI trial. Eur Heart J 1992; 13:1225-1232.
41. Parsons M, Spratt N, Bivard A etal. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012; 366:1099-1107.
42. Antman EM, Anbe DT, Armstrong PW etal. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004; 110:e82-292.
43. Yamaguchi T, Mori E, Minematsu K etal. Alteplase at 0.6mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006; 37:1810-1815.
44. Demchuk AM, Hill MD, Barber PA, Silver B, Patel SC, Levine SR. Importance of early ischemic computed tomography changes using ASPECTS in NINDS rtPA Stroke Study. Stroke 2005; 36:2110-2115.
45. Dzialowski I, Hill MD, Coutts SB etal. Extent of early ischemic changes on computed tomography (CT) before thrombolysis: prognostic value of the Alberta Stroke Program Early CT Score in ECASS II. Stroke 2006; 37:973-978.
46. Berger C, Fiorelli M, Steiner T etal. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke 2001; 32:1330-1335.
47. Organised inpatient (stroke unit) care for stroke. Stroke Unit Trialists' Collaboration. Cochrane Database Syst Rev 2000, issue 2, art. no.: CD000197.